176 related articles for article (PubMed ID: 37798436)
41. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.
Jiffar T; Yilmaz T; Lee J; Hanna E; El-Naggar A; Yu D; Myers JN; Kupferman ME
Oncogene; 2011 Jul; 30(28):3163-73. PubMed ID: 21383688
[TBL] [Abstract][Full Text] [Related]
42. Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial.
Hsieh CY; Lien MY; Lin CY; Lo WJ; Hua CH; Chang WC; Chiu CF; Lin CC
BMC Cancer; 2022 Feb; 22(1):169. PubMed ID: 35168547
[TBL] [Abstract][Full Text] [Related]
43. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
44. Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01).
Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kim HJ; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
Cancer Res Treat; 2022 Jan; 54(1):109-117. PubMed ID: 33940788
[TBL] [Abstract][Full Text] [Related]
45. The relationship of the human glutathione S-transferase P1 polymorphism and chemotherapeutic sensitivity in head and neck squamous carcinoma.
Kimura S; Imagawa Y; Satake K; Tsukuda M
Int J Mol Med; 2004 Aug; 14(2):185-9. PubMed ID: 15254763
[TBL] [Abstract][Full Text] [Related]
46. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Keil F; Hartl M; Altorjai G; Berghold A; Riedl R; Pecherstorfer M; Mayrbäurl B; De Vries A; Schuster J; Hackl J; Füreder T; Melchardt T; Burian M; Greil R
Eur J Cancer; 2021 Jul; 151():201-210. PubMed ID: 34022697
[TBL] [Abstract][Full Text] [Related]
47. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
48. Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma.
Geiger JL; Lazim AF; Walsh FJ; Foote RL; Moore EJ; Okuno SH; Olsen KD; Kasperbauer JL; Price DL; Garces YI; Ma DJ; Neben-Wittich MA; Molina JR; Garcia JJ; Price KA
Oral Oncol; 2014 Apr; 50(4):311-8. PubMed ID: 24467937
[TBL] [Abstract][Full Text] [Related]
49. ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Guberina M; Sak A; Pöttgen C; Tinhofer-Keilholz I; Budach V; Balermpas P; Von der Grün J; Rödel CM; Gkika E; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; De-Colle C; Welz S; Linge A; Lohaus F; Baretton G; Gauler T; Baumann M; Krause M; Schuler M; Bankfalvi A; Höing B; Lang S; Stuschke M
Pharmacogenomics J; 2021 Feb; 21(1):37-46. PubMed ID: 32546699
[TBL] [Abstract][Full Text] [Related]
50. Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study.
Dhawan D; Panchal H; Shukla S; Padh H
Indian J Med Res; 2013 Jan; 137(1):125-9. PubMed ID: 23481061
[TBL] [Abstract][Full Text] [Related]
51. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
Huang X; Liu Q; Zhong G; Peng Y; Liu Y; Liang L; Hong H; Feng W; Yang S; Zhang Y; Xian S; Li Z; Zhou Y; Zhang Z; Jiang W; Liang J; Liu ZG
J Exp Clin Cancer Res; 2022 Oct; 41(1):300. PubMed ID: 36224603
[TBL] [Abstract][Full Text] [Related]
53. Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma.
Harabuchi S; Kosaka A; Yajima Y; Nagata M; Hayashi R; Kumai T; Ohara K; Nagato T; Oikawa K; Ohara M; Harabuchi Y; Ohkuri T; Kobayashi H
Biochem Biophys Res Commun; 2020 Feb; 522(2):408-414. PubMed ID: 31771883
[TBL] [Abstract][Full Text] [Related]
54. DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.
Martens-de Kemp SR; Dalm SU; Wijnolts FM; Brink A; Honeywell RJ; Peters GJ; Braakhuis BJ; Brakenhoff RH
PLoS One; 2013; 8(4):e61555. PubMed ID: 23613873
[TBL] [Abstract][Full Text] [Related]
55. Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma.
Ahn D; Lee GJ; Sohn JH; Lee JE
Cancer Med; 2020 Dec; 9(24):9256-9265. PubMed ID: 33073917
[TBL] [Abstract][Full Text] [Related]
56. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Mizumachi T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H; Homma A
Int J Clin Oncol; 2019 May; 24(5):468-475. PubMed ID: 30656463
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and toxicity of peritumoral delivery of nanoconjugated cisplatin in an in vivo murine model of head and neck squamous cell carcinoma.
Cohen SM; Rockefeller N; Mukerji R; Durham D; Forrest ML; Cai S; Cohen MS; Shnayder Y
JAMA Otolaryngol Head Neck Surg; 2013 Apr; 139(4):382-7. PubMed ID: 23599074
[TBL] [Abstract][Full Text] [Related]
59. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
60. Association of OX40 gene polymorphisms (rs17568G/A and rs229811A/C) with head and neck squamous cell carcinoma.
Faghih Z; Abtahi S; Khademi B; Nikfarjam F; Erfani N
Mol Biol Rep; 2019 Jun; 46(3):2609-2616. PubMed ID: 30923998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
